Biologic agents in the treatment of glomerulonephritides

Nephrology

Volumn 20, Issue 11, 2015, Pages 767-787

  Yeo, See Cheng ^a   Liew, Adrian ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

biologics; glomerulonephritis; immunosuppression

Indexed keywords

ABATACEPT; ADALIMUMAB; ATACICEPT; BELIMUMAB; BIOLOGICAL PRODUCT; BLISIBIMOD; CCX 168; ECULIZUMAB; ETANERCEPT; FOSTAMATINIB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED GLOMERULONEPHRITIS; ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; C3 GLOMERULOPATHY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE DISEASE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECURRENCE RISK; REMISSION; REVIEW; TREATMENT DURATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; PATIENT SAFETY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL PRODUCTS; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SAFETY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84943240351     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12530     Document Type: Review

References (136)

1. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in Systemic Lupus Erythematosus revisited. J. Am. Soc. Nephrol. 2004; 15: 241-250.
2. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in Systemic Lupus Erythematosus revisited. Kidney Int. 2004; 65: 521-530.
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65: 1-11.
4. Couser WG, Johnson RJ,. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney Int. 2014; 86: 905-914.
5. Hogan J, Avasare R, Radhakrishnan J,. Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin. J. Am. Soc. Nephrol. 2014; 9: 1657-1667.
6. Salama AD, Pusey CD,. Drug insight: rituximab in renal disease and transplantation. Nat. Clin. Pract. Nephrol. 2006; 2: 221-230.
7. Hamze M, Desmetz C, Guglielmi P,. B cell-derived cytokines in disease. Eur. Cytokine Netw. 2013; 24: 20-26.
8. Pillai S, Mattoo H, Cariappa A,. B cells and autoimmunity. Curr. Opin. Immunol. 2011; 23: 721-731.
9. Fleischmann RM,. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin. Arthritis Rheum. 2009; 38: 265-280.
10. Toussirot É, Bereau M,. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases. Inflamm. Allergy Drug Targets 2014; 13: 121-127.
11. Tsutsumi Y, Yamamoto Y, Shimono J, et al. Hepatitis B virus reactivation with rituximab-containing regimen. World J. Hepatol. 2013; 5: 612-620.
12. Sellier-Leclerc AL, Belli E, Guérin V, et al. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr. Nephrol. 2013; 28: 1875-1879.
13. Sato M, Ito S, Ogura M, et al. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr. Nephrol. 2013; 28: 145-149.
14. Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology 2008; 47: 1256-1257.
15. Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology 2012; 51: 653-662.
16. Mok MM, Yeung CK, Chan DT, et al. New onset psoriasis after rituximab for treatment of idiopathic membranous nephropathy. Nephrology 2014; 19: 60.
17. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363: 211-220.
18. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363: 221-232.
19. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 2013; 369: 417-427.
20. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012; 64: 3760-3769.
21. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012; 64: 3770-3778.
22. Rhee EP, Laliberte KA, Niles JL,. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin. J. Am. Soc. Nephrol. 2010; 5: 1394-1400.
23. Charles P, Néel A, Tieulié N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology 2014; 53: 532-539.
24. Pendergraft WF 3rd, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin. J. Am. Soc. Nephrol. 2014; 9: 736-744.
25. Guillevin L, Pagnoux A, Karras C, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 2014; 371: 1771-1780.
26. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64: 1215-1226.
27. Roccatello D, Sciascia S, Rossi D, et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol. Dial. Transplant. 2011; 26: 3987-3992.
28. Gunnarsson I, Sundelin B, Jónsdóttir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007; 56: 1263-1272.
29. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009; 61: 482-487.
30. Moroni G, Raffiotta F, Trezzi B, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014; 53: 1570-1577.
31. Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-924.
32. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 2003; 14: 1851-1857.
33. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2012; 23: 1416-1425.
34. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73: 117-125.
35. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 2010; 5: 2188-2198.
36. Bomback AS, Derebail VK, McGregor JG, et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol. 2009; 4: 734-744.
37. Cara-Fuentes G, Kairalla JA, Ishimoto T, et al. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatr. Nephrol. 2014; 29: 1313-1319.
38. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 2011; 3: 85ra46.
39. Chan AC,. Rituximab's new therapeutic target: the podocyte actin cytoskeleton. Sci.Transl. Med. 2011; 3: 85ps21.
40. Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 2011; 6: 1308-1315.
41. Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 2012; 23: 1117-1124.
42. François H, Daugas E, Bensman A, et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am. J. Kidney Dis. 2007; 49: 158-161.
43. Hoxha E, Stahl RA, Harendza S,. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin. Nephrol. 2011; 76: 151-158.
44. Fernandez-Fresnedo G, Segarra A, González E, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2009; 4: 1317-1323.
45. Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 2014; 25: 850-863.
46. Yuling H, Ruijing X, Xiang J, et al. CD19+CD5+ B cells in primary IgA nephropathy. J. Am. Soc. Nephrol. 2008; 19: 2130-2139.
47. Do RK, Hatada E, Lee H, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 2000; 192: 953-964.
48. Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 2000; 192: 1453-1466.
49. Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 2014; 10: 365-373.
50. Goto T, Bandoh N, Yoshizaki T, et al. Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy. Clin. Immunol. 2008; 126: 260-269.
51. Davidson A,. Targeting BAFF in autoimmunity. Curr. Opin. Immunol. 2010; 22: 732-739.
52. Stohl W,. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr. Rheumatol. Rep. 2012; 14: 303-309.
53. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
54. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63: 3918-3930.
55. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J. Rheumatol. 2014; 41: 300-309.
56. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 Trial. J. Rheumatol. 2012; 39: 1632-1640.
57. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22: 63-72.
58. Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann. Rheum. Dis. 2012; 71: 1833-1838.
59. Furie R, Scheinberg M, Leon G, et al. Effects of blisibimod, an inhibitor of B-cell activating factor, on markers of renal disease in patients with SLE. Ann. Rheum. Dis. 2013; 72: A95.
60. Xin G, Shi W, Xu LX, et al. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J. Nephrol. 2013; 26: 683-690.
61. Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 2005; 25: 298-302.
62. Hamour S, Salama AD, Pusey CD,. Management of ANCA-associated vasculitis: current trends and future prospects. Ther. Clin. Risk Manag. 2010; 6: 253-264.
63. Liu L, Zhang Y, Duan X, et al. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J. Clin. Immunol. 2014; 34: 224-232.
64. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840-1847.
65. Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am. J. Hematol. 2010; 85: 553-559.
66. Dmytrijuk A, Robie-Suh K, Cohen MH, et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008; 13: 993-1000.
67. Bouts A, Monnens L, Davin JC, et al. Insufficient protection by Neisseria meningitides vaccination alone during eculizumab therapy. Pediatr. Nephrol. 2011; 26: 1919-1920.
68. Gardner P,. Clinical practice. Prevention of meningococcal disease. N. Engl. J. Med. 2006; 355: 1466-1473.
69. Gruppo RA, Rother RP,. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009; 360: 544-546.
70. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009; 360: 542-544.
71. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013; 368: 2169-2181.
72. Fakhouri F, Delmas Y, Provot F, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am. J. Kidney Dis. 2014; 63: 40-48.
73. Vivarelli M, Pasini A, Emma F,. Eculizumab for the treatment of dense-deposit disease. N. Engl. J. Med. 2012; 366: 1163-1165.
74. Daina E, Noris M, Remuzzi G,. Eculizumab in a patient with dense-deposit disease. N. Engl. J. Med. 2012; 366: 1161-1163.
75. McCaughan JA, O'Rourke DM, Courtney AE,. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am. J. Transplant. 2012; 12: 1046-1051.
76. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin. J. Am. Soc. Nephrol. 2012; 7: 748-756.
77. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J. Am. Soc. Nephrol. 2012; 23: 1229-1237.
78. Lapeyraque AL, Malina M, Fremeauz-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 2011; 364: 2561-2563.
79. Kielstein JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol. Dial. Transplant. 2012; 27: 3807-3815.
80. Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345: e4565.
81. Radhakrishnan S, Lunn A, Kirschfink M, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N. Engl. J. Med. 2012; 366: 1165-1166.
82. Kaplan M,. Eculizumab (Alexion). Curr. Opin. Investig. Drugs 2002; 3: 1017-1023.
83. Barilla-Labarca ML, Toder K, Furie R,. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin. Immunol. 2013; 148: 313-321.
84. Yamada A, Salama AD, Sayegh MH,. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 2002; 13: 559-575.
85. Vincenti F,. Costimulation blockade in autoimmunity and transplantation. J. Allergy Clin. Immunol. 2008; 121: 299-306.
86. Daikh D, Wofsy D, Imboden JB,. The CD28-B7 costimulatory pathway and its role in autoimmune disease. J. Leukoc. Biol. 1997; 62: 156-162.
87. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006; 54: 2807-2816.
88. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2011; (2): CD008794.
89. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 2012; 12: 210-217.
90. Daikh DI, Finck BK, Linsley PS, et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 1997; 159: 3104-3108.
91. Daikh DI, Wofsy D,. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 2001; 166: 2913-2916.
92. Schiffer L, Sinha J, Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 2003; 171: 489-497.
93. Dall'Era M, Davis J,. CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004; 13: 372-376.
94. Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 2004; 113: 1390-1397.
95. Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014; 66: 379-389.
96. Wofsy D, Hillson JL, Diamond B,. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012; 64: 3660-3665.
97. Wofsy D, Hillson JL, Diamond B,. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013; 65: 1586-1591.
98. Langford CA, Monach PA, Specks U, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann. Rheum. Dis. 2014; 73: 1376-1379.
99. Garin EH, Diaz LN, Mu W, et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J. Am. Soc. Nephrol. 2009; 20: 260-266.
100. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. 2013; 369: 2416-2423.
101. Haraldsson B,. A new era of podocyte-targeted therapy for proteinuric kidney disease. N. Engl. J. Med. 2013; 369: 2453-2454.
102. Reiser J, Alachkar N,. Proteinuria: abate or applaud abatacept in proteinuric kidney disease? Nat. Rev. Nephrol. 2014; 10: 128-130.
103. Ernandez T, Mayadas TN,. Immunoregulatory role of TNFalpha in inflammatory kidney diseases. Kidney Int. 2009; 76: 262-276.
104. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000; 43: 2383-2390.
105. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. 2005; 7: R545-551.
106. Solomon AJ, Spain RI, Kruer MC, et al. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult. Scler. 2011; 17: 1472-1487.
107. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNFα therapy for rheumatoid arthritis. Nephrol. Dial. Transplant. 2005; 20: 1400-1406.
108. Weisman MH,. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J. Rheumatol. Suppl. 2002; 65: 33-38.
109. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002; 46: 3151-3158.
110. Wolfe F, Michaud K,. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. Arthritis Rheum. 2004; 50: 1740-1751.
111. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 2005; 352: 351-361.
112. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006; 54: 1608-1618.
113. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 2005; 64: 1414-1420.
114. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002; 41: 1126-1132.
115. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002; 41: 1303-1307.
116. Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann. Rheum. Dis. 2002; 61: 559.
117. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004; 15: 717-721.
118. Gonnet-Gracia C, Barnetche T, Richez C, et al. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin. Exp. Rheumatol. 2008; 26: 401-407.
119. Laurino S, Chaudhry A, Booth A, et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol. Dial. Transplant. 2010; 25: 3307-3314.
120. Hayat SJ, Uppal SS, Narayanan Nampoory MR, et al. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin. Rheumatol. 2007; 26: 973-975.
121. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology 2009; 48: 1451-1454.
122. Aringer M, Smolen JS,. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun. Rev. 2012; 11: 321-325.
123. Lis K, Kuzawińska O, Bałkowiec-Iskra E,. Tumor necrosis factor inhibitors-state of knowledge. Arch. Med. Sci. 2014; 10: 1175-1185.
124. Schmidt CQ, Slingsby FC, Richards A, et al. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr. Purif. 2011; 76: 254-263.
125. Büttner-Mainik A, Parsons J, Jérôme H, et al. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol. J. 2011; 9: 373-383.
126. Kim MJ, McDaid JP, McAdoo SP, et al. Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J. Immunol. 2012; 189: 3751-3758.
127. Smith J, McDaid JP, Bhangal G, et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J. Am. Soc. Nephrol. 2010; 21: 231-236.
128. Deng GM, Liu L, Bahjat FR, et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010; 62: 2086-2092.
129. Sumida K, Ubara Y, Takemoto F, et al. Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin. Exp. Rheumatol. 2011; 29 (1 Suppl 64): S133.
130. Tanna A, Tam FW, Pusey CD,. B-cell-targeted therapy in adult glomerulonephritis. Expert Opin. Biol. Ther. 2013; 13: 1691-1706.
131. Wallace DJ, Goldenberg DM,. Epratuzumab for systemic lupus erythematosus. Lupus 2013; 22: 400-405.
132. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 2012; 14: R33.
133. Feehally J,. Targeted therapies: Is there a role for rituximab in nephrotic syndrome? Nat Rev Nephrol 2014; 10: 245-247.
134. Jayne D,. New-generation therapy for ANCA-associated vasculitis. Clin. Exp. Nephrol. 2013; 17: 694-696.
135. Caliskan Y, Kiryluk K,. Novel biomarkers in glomerular disease. Adv. Chronic Kidney Dis. 2014; 21: 205-216.
136. McAdoo SP, Pusey CD,. Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis? Clin. J. Am. Soc. Nephrol. 2014; 9: 641-644.